{
  "symbol": "SLDB",
  "company_name": "Solid Biosciences Inc",
  "ir_website": "https://investors.solidbio.com/",
  "structured_data": [
    {
      "section_name": "Overview & News",
      "links": [
        {
          "title": "Overview",
          "url": "https://investors.solidbio.com/investor-relations",
          "content": "![](sites/g/files/knoqqb87196/themes/site/client_site_202/dist/images/lab--1700x800.jpg)\n\n[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nInvestor Relations \n\n## A precision genetic medicine company focused on neuromuscular and cardiac diseases\n\nSolid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases.\n\n## Stock Information\n\n![Image Stock Chart](https://api.nasdaqomx.wallst.com/api/chart?display=mountain&symbol=SLDB&scale=linear&duration=1dy&frequency=15min&gridLine=h&bgColor=ffffff&lineColor=ff6d53&fillcolor=ff6d53|ffffff&width=560&height=320&&volume=0&bdr=0&fontColor=000000&bdrcolor=ffffff)\n\nNASDAQ: SLDB\n\n$5.71 + 0.02 (+0.35%)\n\nMinimum 15 minutes delayed. Source: LSEG\n\n## Press Releases\n\nNov 26\n\n[Solid Biosciences to Participate at Upcoming Investor Conferences](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-5)\n\nCHARLESTOWN, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Citi’s \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-5)\n\nNov 14\n\n[Solid Biosciences to Present at the Jefferies London Healthcare Conference](/news-releases/news-release-details/solid-biosciences-present-jefferies-london-healthcare-conference)\n\nCHARLESTOWN, Mass. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks , \n\n[Read More](/news-releases/news-release-details/solid-biosciences-present-jefferies-london-healthcare-conference)\n\n[View All News](/news-and-events/press-releases)\n\n## Presentations\n\n[Solid Biosciences November 2024 Corporate Presentation](/static-files/21fe0dbb-b1a8-4d3b-88e8-9d7eef02110a)\n\nNovember 8, 2024\n\n## Events\n\nDec 5 9:30 AM EST\n\nPiper Sandler 36th Annual Healthcare Conference\n\n[Listen to Webcast](https://event.webcasts.com/starthere.jsp?ei=1699325&tp_key=c4a6331a40)\n\nDec 4 1:00 PM EST\n\nCiti’s 2024 Global Healthcare Conference\n\n[Listen to Webcast](https://kvgo.com/2024-global-healthcare-conference/solid-bio-december)\n\nNov 20 1:30 PM GMT\n\nJefferies London Healthcare Conference\n\n[Listen to Webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=sldb&url=https%3A//wsw.com/webcast/jeff315/sldb/1834980)\n\n[View All Events](/news-and-events/events)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Press Releases",
          "url": "https://investors.solidbio.com/news-and-events/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nPress Releases \n\nYear All2024202320222021202020192018201720162015\n\n2024\n\nNov 26\n\n[Solid Biosciences to Participate at Upcoming Investor Conferences](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-5)\n\nCHARLESTOWN, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Citi’s \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-5)\n\nNov 14\n\n[Solid Biosciences to Present at the Jefferies London Healthcare Conference](/news-releases/news-release-details/solid-biosciences-present-jefferies-london-healthcare-conference)\n\nCHARLESTOWN, Mass. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks , \n\n[Read More](/news-releases/news-release-details/solid-biosciences-present-jefferies-london-healthcare-conference)\n\nNov 06\n\n[Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/solid-biosciences-reports-third-quarter-2024-financial-results)\n\n- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: Activities undertaken to accelerate development of SGT-003, including: expansion \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-third-quarter-2024-financial-results)\n\nNov 04\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-5)\n\nCHARLESTOWN, Mass. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 9,741 restricted stock units (“RSUs”) to one newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-5)\n\nOct 31\n\n[Solid Biosciences to Participate at the Truist Securities BioPharma Symposium](/news-releases/news-release-details/solid-biosciences-participate-truist-securities-biopharma)\n\nCHARLESTOWN, Mass. , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Gabriel Brooks , M.D., Chief Medical Officer, will \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-truist-securities-biopharma)\n\nOct 02\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-4)\n\nCHARLESTOWN, Mass. , Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 51,338 restricted stock units (“RSUs”) to three newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-4)\n\nSep 23\n\n[Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference](/news-releases/news-release-details/solid-biosciences-participate-chardans-8th-annual-genetic)\n\nCHARLESTOWN, Mass. , Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and CEO, and Gabriel Brooks , \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-chardans-8th-annual-genetic)\n\nSep 12\n\n[Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference](/news-releases/news-release-details/solid-biosciences-participate-2024-cantor-global-healthcare)\n\nCHARLESTOWN, Mass. , Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo , President and CEO, and Gabriel Brooks , \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-2024-cantor-global-healthcare)\n\nSep 04\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-3)\n\nCHARLESTOWN, Mass. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 42,082 restricted stock units (“RSUs”) to three newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-3)\n\nSep 04\n\n[Solid Biosciences to Participate at Upcoming Investor Conferences](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-4)\n\nCHARLESTOWN, Mass. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: H.C. \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-4)\n\nAug 13\n\n[Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates](/news-releases/news-release-details/solid-biosciences-reports-second-quarter-2024-financial-results)\n\n– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4 2024 – – Solid plans to expand patient dosing with additional clinical trial sites in the U.S. \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-second-quarter-2024-financial-results)\n\nAug 05\n\n[Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grant-under-nasdaq-0)\n\nCHARLESTOWN, Mass. , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 86,665 restricted stock units (“RSUs”) to four newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grant-under-nasdaq-0)\n\nJul 01\n\n[Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grant-under-nasdaq-listing)\n\nCHARLESTOWN, Mass. , July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“RSUs”) to one newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grant-under-nasdaq-listing)\n\nJul 01\n\n[Solid Biosciences Joins the Russell 3000® Index](/news-releases/news-release-details/solid-biosciences-joins-russell-3000r-index)\n\nCHARLESTOWN, Mass. , July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as part of \n\n[Read More](/news-releases/news-release-details/solid-biosciences-joins-russell-3000r-index)\n\nJun 04\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-2)\n\nCHARLESTOWN, Mass. , June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 30,949 restricted stock units (“RSUs”) to four newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-2)\n\nMay 15\n\n[Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results](/news-releases/news-release-details/solid-biosciences-provides-first-quarter-2024-business-update)\n\n— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary, muscle- targeted \n\n[Read More](/news-releases/news-release-details/solid-biosciences-provides-first-quarter-2024-business-update)\n\nMay 07\n\n[Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting](/news-releases/news-release-details/solid-biosciences-present-american-society-gene-and-cell-0)\n\n— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates, and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — CHARLESTOWN, Mass. , May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. \n\n[Read More](/news-releases/news-release-details/solid-biosciences-present-american-society-gene-and-cell-0)\n\nMay 02\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-1)\n\nCHARLESTOWN, Mass. , May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-1)\n\nApr 03\n\n[Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-0)\n\nCHARLESTOWN, Mass. , April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. \n\n[Read More](/news-releases/news-release-details/solid-biosciences-reports-inducement-grants-under-nasdaq-0)\n\nApr 01\n\n[Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003](/news-releases/news-release-details/solid-biosciences-receives-rare-pediatric-disease-designation)\n\n– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass. , April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company \n\n[Read More](/news-releases/news-release-details/solid-biosciences-receives-rare-pediatric-disease-designation)\n\nMar 27\n\n[Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium](/news-releases/news-release-details/solid-biosciences-participate-cantors-virtual-muscular-dystrophy)\n\nCHARLESTOWN, Mass. , March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks , M.D., \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-cantors-virtual-muscular-dystrophy)\n\nMar 13\n\n[Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results](/news-releases/news-release-details/solid-biosciences-provides-fourth-quarter-and-full-year-2023)\n\n— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne \n\n[Read More](/news-releases/news-release-details/solid-biosciences-provides-fourth-quarter-and-full-year-2023)\n\nMar 07\n\n[Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD](/news-releases/news-release-details/solid-biosciences-announces-licensing-agreement-armatus-bio-use)\n\nCHARLESTOWN, Mass. , March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for \n\n[Read More](/news-releases/news-release-details/solid-biosciences-announces-licensing-agreement-armatus-bio-use)\n\nMar 06\n\n[Solid Biosciences to Participate at Upcoming Investor Conferences](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-3)\n\nCHARLESTOWN, Mass. , March 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Leerink Partners Global \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-3)\n\nJan 16\n\n[Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003](/news-releases/news-release-details/solid-biosciences-granted-fda-orphan-drug-designation-duchenne)\n\n– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted \n\n[Read More](/news-releases/news-release-details/solid-biosciences-granted-fda-orphan-drug-designation-duchenne)\n\nJan 08\n\n[Solid Biosciences Announces $109 Million Private Placement](/news-releases/news-release-details/solid-biosciences-announces-109-million-private-placement)\n\nCHARLESTOWN, Mass. , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of \n\n[Read More](/news-releases/news-release-details/solid-biosciences-announces-109-million-private-placement)\n\nJan 04\n\n[Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference](/news-releases/news-release-details/solid-biosciences-participate-42nd-annual-jp-morgan-healthcare)\n\nCHARLESTOWN, Mass. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan \n\n[Read More](/news-releases/news-release-details/solid-biosciences-participate-42nd-annual-jp-morgan-healthcare)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Presentations",
          "url": "https://investors.solidbio.com/news-and-events/presentations",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nPresentations \n\n[Solid Biosciences November 2024 Corporate Presentation](/static-files/21fe0dbb-b1a8-4d3b-88e8-9d7eef02110a)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Events",
          "url": "https://investors.solidbio.com/news-and-events/events",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nEvents \n\n## Upcoming Events\n\nDec 4 1:00 PM EST\n\nCiti’s 2024 Global Healthcare Conference\n\n[Listen to Webcast](https://kvgo.com/2024-global-healthcare-conference/solid-bio-december)\n\nDec 5 9:30 AM EST\n\nPiper Sandler 36th Annual Healthcare Conference\n\n[Listen to Webcast](https://event.webcasts.com/starthere.jsp?ei=1699325&tp_key=c4a6331a40)\n\n## Past Events\n\nNov 20 1:30 PM GMT\n\n[Jefferies London Healthcare Conference](/events/event-details/jefferies-london-healthcare-conference-0)\n\n[Listen to Webcast](https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=sldb&url=https%3A//wsw.com/webcast/jeff315/sldb/1834980)\n\nSep 30 11:00 AM EDT\n\n[Chardan’s 8th Annual Genetic Medicines Conference](/events/event-details/chardans-8th-annual-genetic-medicines-conference)\n\n[Listen to Webcast](https://wsw.com/webcast/chard19/register.aspx?conf=chard19&page=sldb&url=https%3A//wsw.com/webcast/chard19/sldb/1906940)\n\nSep 18 10:20 AM EDT\n\n[2024 Cantor Global Healthcare Conference](/events/event-details/2024-cantor-global-healthcare-conference)\n\n[Listen to Webcast](https://wsw.com/webcast/cantor22/register.aspx?conf=cantor22&page=sldb&url=https%3A//wsw.com/webcast/cantor22/sldb/2070135)\n\nSep 10 9:30 AM EDT\n\n[ H.C. Wainwright 26th Annual Global Investment Conference](/events/event-details/solid-biosciences-hc-wainwright-26th-annual-global-investment-conference)\n\n[Listen to Webcast](https://journey.ct.events/view/b4615043-8799-4a20-8a4e-25e9da19f4d7)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        }
      ]
    },
    {
      "section_name": "Governance & Financials",
      "links": [
        {
          "title": "Governance Documents",
          "url": "https://investors.solidbio.com/governance/governance-documents",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nGovernance & Financials:\n\nGovernance Documents \n\nThe Board of Directors of Solid Biosciences Inc. (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for stockholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n[Code of Business Conduct and Ethics](/static-files/f3ccdee0-e81c-42ff-8128-82c197d65c20)\n\n[Corporate Governance Guidelines](/static-files/6e160790-1c47-4619-9226-e4d0c58a99e4)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Committee Charters",
          "url": "https://investors.solidbio.com/governance/committee-charters",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nGovernance & Financials:\n\nCommittee Charters \n\n[Audit Committee Charter](/static-files/25a23a73-1d7c-437a-a208-a9f4d0678e1c)\n\n[Clinical Committee Charter ](/static-files/f112476c-76ea-45b6-98a9-520ca939364a)\n\n[Compensation Committee Charter](/static-files/533dd430-e2b7-43d3-bfb7-c838dd899c73)\n\n[Nominating and Corporate Governance Committee Charter](/static-files/601fd2a4-276d-49f9-94e4-01ffac815020)\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://investors.solidbio.com/governance/committee-composition",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nGovernance & Financials:\n\nCommittee Composition \n\nDirector Name | [Audit Committee](/static-files/25a23a73-1d7c-437a-a208-a9f4d0678e1c) | [Clinical Committee ](/static-files/f112476c-76ea-45b6-98a9-520ca939364a) | [Compensation Committee](/static-files/533dd430-e2b7-43d3-bfb7-c838dd899c73) | [Nominating and Corporate Governance Committee](/static-files/601fd2a4-276d-49f9-94e4-01ffac815020)  \n---|---|---|---|---  \nMartin Freed, M.D., F.A.C.P.  | Chair of the [Clinical Committee ](/static-files/f112476c-76ea-45b6-98a9-520ca939364a) | Member of the [Compensation Committee](/static-files/533dd430-e2b7-43d3-bfb7-c838dd899c73)  \nClare Kahn, Ph.D.  | Member of the [Clinical Committee ](/static-files/f112476c-76ea-45b6-98a9-520ca939364a) | Member of the [Nominating and Corporate Governance Committee](/static-files/601fd2a4-276d-49f9-94e4-01ffac815020)  \nGeorgia Keresty, Ph.D.  | Member of the [Audit Committee](/static-files/25a23a73-1d7c-437a-a208-a9f4d0678e1c) | Chair of the [Compensation Committee](/static-files/533dd430-e2b7-43d3-bfb7-c838dd899c73)  \nSukumar Nagendran, M.D.  | Member of the [Clinical Committee ](/static-files/f112476c-76ea-45b6-98a9-520ca939364a) | Member of the [Compensation Committee](/static-files/533dd430-e2b7-43d3-bfb7-c838dd899c73)  \nAdam Stone  | Member of the [Audit Committee](/static-files/25a23a73-1d7c-437a-a208-a9f4d0678e1c) | Chair of the [Nominating and Corporate Governance Committee](/static-files/601fd2a4-276d-49f9-94e4-01ffac815020)  \nLynne Sullivan  | Chair of the [Audit Committee](/static-files/25a23a73-1d7c-437a-a208-a9f4d0678e1c) | Member of the [Nominating and Corporate Governance Committee](/static-files/601fd2a4-276d-49f9-94e4-01ffac815020)  \n  \nLegend = Chair = Member\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "SEC Filings",
          "url": "https://investors.solidbio.com/financial-information/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nGovernance & Financials:\n\nSEC Filings \n\nGroup All3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nAll\n\nFiling year All20242023202220212020201920182017\n\nAll\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort By Filing Date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort By Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort By Form\") | View  \n---|---|---|---  \nNov 19, 2024 |  Statement of changes in beneficial ownership of securities |  [4](/sec-filings/sec-filing/4/0001062993-24-019352) |  [0001062993-24-019352.pdf](/static-files/c70f796a-f8a0-49fa-8a24-ff02ba1f9cae) [0001062993-24-019352.rtf](/static-files/eb2bc5df-9ee8-477a-b4ed-7fcb77dd6f60) [0001062993-24-019352.xls](/static-files/896ec33d-e949-4655-8874-d1983b936023) [View HTML](/node/10856/html)  \nNov 19, 2024 |  Statement of changes in beneficial ownership of securities |  [4](/sec-filings/sec-filing/4/0001062993-24-019353) |  [0001062993-24-019353.pdf](/static-files/5a04917b-41eb-4cd9-a569-9933d82da33c) [0001062993-24-019353.rtf](/static-files/dd61f380-392c-40ae-a0fe-2cb02350511d) [0001062993-24-019353.xls](/static-files/7dea0fbf-1a4a-4e6d-a77a-3b4e1e2f53ed) [View HTML](/node/10861/html)  \nNov 14, 2024 |  An amendment to the SC 13G filing |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001193805-24-001357) |  [0001193805-24-001357.pdf](/static-files/8ad6792d-b0b1-49e2-a340-4a38db66bf98) [0001193805-24-001357.rtf](/static-files/a277b867-9ad6-48ac-abd0-c3add17b267d) [0001193805-24-001357.xls](/static-files/fbe93512-5fd8-443f-90d4-6b01d85cffa6) [View HTML](/node/10841/html)  \nNov 14, 2024 |  A statement of beneficial ownership of common stock by certain persons |  [SC 13G](/sec-filings/sec-filing/sc-13g/0000902664-24-006562) |  [0000902664-24-006562.pdf](/static-files/fb78758d-9054-471c-a3f4-c5838fb123f3) [0000902664-24-006562.rtf](/static-files/83cada29-d7de-4bcb-a0c8-9294b0b5877e) [0000902664-24-006562.xls](/static-files/0d6974f7-615e-4196-ae95-7affffc0a3f8) [View HTML](/node/10846/html)  \nNov 14, 2024 |  An amendment to a SC 13D filing |  [SC 13D/A](/sec-filings/sec-filing/sc-13da/0001193125-24-259014) |  [0001193125-24-259014.pdf](/static-files/bf29e4e8-efc6-40e3-aa2f-692ec2c47cf5) [0001193125-24-259014.rtf](/static-files/9563b099-1fee-4399-9af6-482034cac5a5) [0001193125-24-259014.xls](/static-files/889be9b8-1cb3-4d53-ace0-9bec9fae354f) [View HTML](/node/10851/html)  \nNov 12, 2024 |  An amendment to the SC 13G filing |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000902664-24-006394) |  [0000902664-24-006394.pdf](/static-files/b2f1cd75-5d6e-422a-bbb8-6a8e99db9392) [0000902664-24-006394.rtf](/static-files/bb06c0d3-fa40-43d5-831a-a5e65580dccd) [0000902664-24-006394.xls](/static-files/ed4b6618-a1ce-491d-8957-527a50961494) [View HTML](/node/10821/html)  \nNov 12, 2024 |  An amendment to the SC 13G filing |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001193125-24-256066) |  [0001193125-24-256066.pdf](/static-files/922c8f77-98b1-4370-b8cf-22a654634296) [0001193125-24-256066.rtf](/static-files/85c2b418-bb57-463b-a6a8-ea6bf602eaa7) [0001193125-24-256066.xls](/static-files/0bc56bb0-c378-43aa-a35c-8c402569bc7b) [View HTML](/node/10826/html)  \nNov 06, 2024 |  Quarterly report which provides a continuing view of a company's financial position |  [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-122247) |  [0000950170-24-122247.pdf](/static-files/78dc1597-ab0d-4899-9373-ca965af927c0) [0000950170-24-122247.rtf](/static-files/87ded015-5bbe-4890-8684-093b9a28e39f) [0000950170-24-122247.xls](/static-files/71ff806e-4d88-48c0-8453-f35b9f9e797d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-122247) [View HTML](/node/10816/html)  \nNov 01, 2024 |  An amendment to the SC 13G filing |  [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001273087-24-000112) |  [0001273087-24-000112.pdf](/static-files/79f8cff7-8bd2-4dbe-8b3b-df1803f6c176) [0001273087-24-000112.rtf](/static-files/f5a8b7c2-1168-43a1-85e6-1695b862f5a7) [0001273087-24-000112.xls](/static-files/84fe11ac-e29c-48e9-80d7-453294f8c36b) [View HTML](/node/10801/html)  \nOct 22, 2024 |  Statement of changes in beneficial ownership of securities |  [4](/sec-filings/sec-filing/4/0000950170-24-116246) |  [0000950170-24-116246.pdf](/static-files/48c11d16-ed41-41bd-b5bf-42eb0927efd3) [0000950170-24-116246.rtf](/static-files/8d4a8039-0da6-4090-9326-34b37c6f3343) [0000950170-24-116246.xls](/static-files/631be22b-6e3d-4e8f-95f5-65d3490b72ab) [View HTML](/node/10791/html)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Quote Chart",
          "url": "https://investors.solidbio.com/stock-information/stock-quote-chart",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nStock Information:\n\nStock Quote & Chart \n\nChange\n\nVolume\n\nToday's Open\n\nPrevious Close\n\nToday's High\n\nToday's Low\n\n52 Week High\n\n52 Week Low\n\nMinimum 15 minutes delayed. Source: LSEG\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Historical Price Lookup",
          "url": "https://investors.solidbio.com/stock-information/historical-price-lookup",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nStock Information:\n\nHistorical Price Lookup \n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nNovember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\n29\n\nLookup Year 2018201920202021202220232024\n\n2024\n\nLeave this field blank\n\n## Week of November 25, 2024\n\nClosing Price | $5.86 | Volume | 565,207  \n---|---|---|---  \nDay High | $6.11 | Open Price | $5.54  \nDay Low | $5.40 | Split Adjustment Factor | 1:1  \n  \n## Week of November 26, 2024\n\nClosing Price | $5.78 | Volume | 237,678  \n---|---|---|---  \nDay High | $6.00 | Open Price | $5.86  \nDay Low | $5.69 | Split Adjustment Factor | 1:1  \n  \n## Week of November 27, 2024\n\nClosing Price | $5.69 | Volume | 95,013  \n---|---|---|---  \nDay High | $5.89 | Open Price | $5.85  \nDay Low | $5.65 | Split Adjustment Factor | 1:1  \n  \nNOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.\n\nMinimum 15 minutes delayed. Source: LSEG\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://investors.solidbio.com/stock-information/analyst-coverage",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nStock Information:\n\nAnalyst Coverage \n\nFirm | Analyst  \n---|---  \nBarclays  |  Gena Wang, PhD, CFA   \nCantor Fitzgerald & Co. |  Charles C. Duncan, Ph.D.   \nChardan Capital Markets |  Geulah Livshits, Ph.D.   \nCiti Research  \nH.C. Wainwright & Co.  |  Arthur He, Ph.D.   \nJefferies |  Maury Raycroft, Ph.D.   \nJ.P. Morgan |  Anupam Rama   \nLeerink Partners |  Joseph Schwartz   \nPiper Sandler  |  Biren Amin   \nWilliam Blair |  Sami Corwin   \n  \nSolid Biosciences Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Solid Biosciences Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Solid Biosciences Inc. or its management. Solid Biosciences Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://investors.solidbio.com/investor-resources/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nInvestor Resources:\n\nInvestor FAQs \n\nPress space to expand and collapse this section\n\nWhere is Solid Biosciences corporate headquarters? \n\nOur corporate headquarters are located at 500 Rutherford Avenue Third Floor, Charlestown, MA 02129, USA.\n\nTelephone: +1 617 337 4680\n\nPress space to expand and collapse this section\n\nWhen was Solid Biosciences founded? \n\nWe were originally founded in March 2013.\n\nPress space to expand and collapse this section\n\nWhere was Solid Biosciences incorporated?\n\nSolid Biosciences was incorporated in Delaware and converted to a corporation in connection with our initial public offering in January 2018.\n\nPress space to expand and collapse this section\n\nWhen did Solid Biosciences go public? What was the price?\n\nSolid Biosciences’ Initial Public Offering occurred on January 25, 2018 at a price of $16.00 per share.\n\nPress space to expand and collapse this section\n\nWhat is Solid Biosciences’ fiscal year?\n\nOur fiscal year ends December 31st.\n\nPress space to expand and collapse this section\n\nHow is Solid Biosciences’ stock traded?\n\nOur common stock is listed on the Nasdaq Global Select Market under the symbol “SLDB”, and our CUSIP number is 83422E 105.\n\nPress space to expand and collapse this section\n\nWho is Solid Biosciences’ transfer agent? \n\nCommunications regarding transfer requirements, lost certificates and change of address should be directed to: Computershare Trust Company, N.A. 250 Royall Street Canton, MA 02021 (800) 962-4284\n\nPress space to expand and collapse this section\n\nWho is Solid Biosciences’ auditor?\n\nThe auditor for Solid Biosciences is PricewaterhouseCoopers, LLP located in Boston, Massachusetts.\n\nPress space to expand and collapse this section\n\nWho is Solid Biosciences’ legal counsel?\n\nThe legal counsel for Solid Biosciences is Wilmer Cutler Pickering Hale and Dorr LLP located in Boston, Massachusetts.\n\nPress space to expand and collapse this section\n\nWhere can I find out more about Solid Biosciences?\n\nTo find out more about Solid Biosciences visit our webpage at [www.solidbio.com](https://solidbio.com/)\n\nPress space to expand and collapse this section\n\nWhere can I get the latest corporate news releases and financial reports?\n\nSolid Biosciences’ press release archive can be viewed under the “News & Events” section of the “Investor Relations” page and financial reports are available under the Financials section located at our website [www.solidbio.com](https://solidbio.com/)\n\nPress space to expand and collapse this section\n\nHow can I view documents Solid Biosciences has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?\n\nSolid Biosciences’ SEC Filings can be found on [www.sec.gov](https://www.sec.gov/) and are also available under the “Financials” section of the “Investor Relations” page located at our website [www.solidbio.com](https://solidbio.com/)\n\nPress space to expand and collapse this section\n\nWho makes up the Solid Biosciences’ Executive Management team and Board of Directors?\n\nFor a list of the Executive Management team and Board of Directors please visit the “About Us” tab of our website.\n\nPress space to expand and collapse this section\n\nWhom should I contact regarding investor inquiries?\n\nFor investor inquiries please contact: \n\n**Nicole Anderson** Director of Investor Relations & Corporate Communications investors@solidbio.com\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Contact Solid Biosciences",
          "url": "https://investors.solidbio.com/investor-resources/contact-solid-biosciences",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nInvestor Resources:\n\nContact Solid Biosciences \n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.solidbio.com/investor-resources/email-alerts",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nInvestor Resources:\n\nEmail Alerts \n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nEvent  \nNews  \nWeekly Summary  \n  \nEmail\n\nFirst Name\n\nLast Name\n\nTitle\n\nCompany\n\nInvestor type - Select -Individual InvestorBuy-Side AnalystSell-Side AnalystPortfolio ManagerStock BrokerEmployeeNews MediaLibraryOther\n\n- Select -\n\nLeave this field blank\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Solid Biosciences to Participate at Upcoming Investor Conferences",
          "url": "https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-participate-upcoming-investor-conferences-5",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nPress Release \n\n## \n\nSolid Biosciences to Participate at Upcoming Investor Conferences\n\nNovember 26, 2024\n\n[PDF Version](/node/10876/pdf)\n\nCHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:\n\n  * **Citi’s 2024 Global Healthcare Conference – Miami, FL**Bo Cumbo, President and CEO, will participate in a panel discussion titled “Neuromuscular Disorders” on Wednesday, December 4, 2024, at 1:00 p.m. ET.\n\n\n  * **Piper Sandler 36****th****Annual Healthcare Conference – New York, NY**Mr. Cumbo and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 5, 2024, at 9:30 a.m. ET.\n\n\n\nLive webcasts of the Citi panel discussion and Piper Sandler fireside chat will be available on the Events page of the Investors section of the Company website or by [clicking here](https://www.globenewswire.com/Tracker?data=cIy-tilbpVaPOKnibdUqyKxoXnldSZjP2J1two7ud5NKphUEsY1fi0FuyCZWKryInuSV7SuCBmTOgPkbc9r8_dJMcwGcMTht34K1BifNlPrPaOcueEpRXOM3dxQUddXn). A webcast replay will be archived for 30 days on the Events page.\n\nInstitutional investors interested in meeting with management during the conference may reach out to their Citi or Piper Sandler representatives.\n\n**About Solid Biosciences**Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit [www.solidbio.com](https://www.globenewswire.com/Tracker?data=uUlrXhJm9Eo1r4-icLD6kCALOfSqGzF_Z22Bl3wNv-fn6mGYd8mx24PK3rIXDnXGaXXb6yMFTYXAE5onK45PXg==).\n\n**Solid Biosciences Investor Contact:** Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.[investors@solidbio.com](https://www.globenewswire.com/Tracker?data=CkEpGwpdX-dbbxmv_nk685kY276Xpr-Z2Rl9ypu5v9bT88OTzQHZ52cBcqyi7CAFn_Rs3o4FfcOQdGeWKuHyqjFioVy2zivObnnaxNg4hE9ESH7lIIIiOcYfRjV9KY-xB_51aNIDlSpvEnfTiOQhYOZaOYCsId5Fhb3d-uG3MeydWqtJA1ehVITXzU0d90uohaym3cHWgCvhSQGKQ-71IB0VyRhTTX0V5cWaaKD9TlqvFdvszLC63EY2kNCQDI4pUvGVlIsQZqG1aVudOnwGsQ==)\n\n**Media Contact:** Glenn SilverFINN Partners[glenn.silver@finnpartners.com](https://www.globenewswire.com/Tracker?data=NpSJfVWGptmlHwlfi_VhX1SqeDNwY65sa1rf81MiIr9i4fq8XV2sxsFR2w4KBzOQPA3nQEC27-DW0k5v4FJNeB8LdRcplDeKZcw-0WXPw_W1qh4yernWTyCJKQz6BT0BH0nwAh2xTziuKhIHLYy-sazHMDSxwPgQqoXUIruBkCqA27QaXKT3s_Uq8Svi1_WDgVeqNa1az9vCpIK2Vvkifv6RnQn_VhuMq8NAiYn7CmLYAc932ItzwVeBy5BZULhOqAB-Re9g3sOfK15Ozric1gBrz18daLJJP2AH16n4MjY=)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI4OTc5OSM2NjEwMzk0IzIwOTExOTc=)![](https://ml.globenewswire.com/media/NGIyZDM5ZDMtOGU5MC00ZTExLWFkNTktYTEyOTdiNGQxN2Y5LTExMDI3Njg=/tiny/Solid-Biosciences-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb/small/solid-1029x579-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb)\n\nSource: Solid Biosciences Inc.\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        },
        {
          "title": "Solid Biosciences to Present at the Jefferies London Healthcare Conference",
          "url": "https://investors.solidbio.com/news-releases/news-release-details/solid-biosciences-present-jefferies-london-healthcare-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ](https://www.solidbio.com/)\n\nAbout  Our Science  Patient & Caregiver Resources  Investors & Media \n\n# \n\nOverview & News:\n\nPress Release \n\n## \n\nSolid Biosciences to Present at the Jefferies London Healthcare Conference\n\nNovember 14, 2024\n\n[PDF Version](/node/10836/pdf)\n\nCHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET).\n\nA live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by [clicking here](https://www.globenewswire.com/Tracker?data=ijv2SYnScvvt_rzZauvB5nYcd2Rp9_cIZ2l4UVJAmeulZ3mP13sOygd-fxoNxmg323ueoHcOMpYBwQerUGXmVQf3cQcRDFqcTRt2_5xX9CTdUya9UjY83KK2K1lO5-93y249sa-F2q88C5z1H-aIfugzlnqKfXdf61_Ys22tRhFgax5l_e_HWrpA_vFv5ds_IQ_OpbLIRqKUVQ8dRfUMvw==). A webcast replay will be archived for 30 days on the Events page.\n\nInstitutional investors interested in meeting with management during the conference may reach out to their Jefferies representatives.\n\n**About Solid Biosciences**Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit [www.solidbio.com](https://www.globenewswire.com/Tracker?data=u1aF0yG9pBxz7hz8FdVfdqNzQKnLbdyIrkSTTaAIpRgt_TE_nzI_3msLFAlxFHMuu38jpnj4qwl4-dyydjjXeBYIYXfCDHQi-dd360xYmjh1ZBX42fkmusEUwlfn4Ru7lxgiv-lI1cn_jl8FHxD7X8ZSmxloM53VRyy26jSjeyWclieSycxzKeKQP5chgdNTTMIVsLriVB6xmMB9jhRH9z8tuzaVjUh_-jFVOCcs8EY=).\n\n**Solid Biosciences Investor Contact:** Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.[investors@solidbio.com](https://www.globenewswire.com/Tracker?data=hyj4Rmpak1iFjaglySZXeyvlaQQQSU6TUyOiEaW186KnSHitmQt_lzmfd8tmBZOgnQ_jpgykxDr20Xe64y2pyoEKr6ccVCvorwqEyc6mXxBKCWCzd2fFLe_4i5vmkxqlnD2pALF65yrVNINOErJtgBlCSEAQMhpa8a1nr4OJ-WCyVPz3vDRiCyJTkQuSm83YAQAPn4KzG7wBfJMyjje6yqGlfPpu7iVY-2ZQ-ysXSLDK-KV8T2uM6fsRYckDooRsqzq2tbgLERSjAm5EPn2skw==)\n\n**Media Contact:** Glenn SilverFINN Partners[glenn.silver@finnpartners.com](https://www.globenewswire.com/Tracker?data=5u4Fr1fj5UUchi9xb_guuiaI0pkZnBNn44Gfg7SHkx5TCv9Qdc8NAfS4PSY5tpfOOmdRWQxqDmeewvw9rDLlvllsr5-WOLabqOZ5tNPW6fZ90dfFO2-C3Uxl9coLBQGztJrotKNfLMS6NQDguhxDDItTWTcF8f83Ikxu2k3pRbyy2hYbgnn6_m4W9HfWPdqSBEckCBjIzVTIgYus6sC5nbqEVP3_-g8gkDumpyhNl3R-it8tEJUdr9frGw-DmtYaIsa1CCt2v3AChtusLLN3251j9-ACOzJoQdOD4uF1Eko=)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI3MzM2OCM2NTgxMjc5IzIwOTExOTc=)![](https://ml.globenewswire.com/media/N2EyZjkyODMtOWMxMi00OWUwLWE2MDAtNzk1MDNiOWMwNWVmLTExMDI3Njg=/tiny/Solid-Biosciences-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb/small/solid-1029x579-png.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb)\n\nSource: Solid Biosciences Inc.\n\nThis website stores cookies on your computer. These cookies, which also could include third party cookies, are used (among other purposes) to improve the website and provide more personalized services to you. To find out more about how we use cookies and how to change your settings, see our [Privacy Policy](https://www.notified.com/privacy).\n\nI accept\n"
        }
      ]
    },
    {
      "section_name": "Presentations",
      "links": [
        {
          "title": "Solid Biosciences November 2024 Corporate Presentation",
          "url": "https://investors.solidbio.com/static-files/21fe0dbb-b1a8-4d3b-88e8-9d7eef02110a",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://event.webcasts.com/starthere.jsp?ei=1699325&tp_key=c4a6331a40",
          "content": "![](https://cache.webcasts.com/content/gwgg002/1699325/content/c4a6331a40ddbccd664b29029fbaa92e3aa3d479/banner/HealthcareWebcastBanner2024.png)\n\n# Solid Biosciences Inc. (SLDB)\n\n## Thu, Dec 5, 2024 9:30 AM EST (8:00 PM Asia/Calcutta) \n\n[![Add to Calendar](https://event.webcasts.com/images/btn_add-to-calendar.png) Add to Calendar](https://event.webcasts.com/viewer/vcs.jsp?ei=1699325&reminderid=0)\n\n## Already Registered? Log In Now\n\nEmail:\n\n## Complete this form to enter the webcast.  (* indicates required field)\n\nFirst Name*: Last Name*: Company*: Email*:\n\n[FAQs and System Test](#)\n\n[![Webcast by GlobalMeet](/viewer/images/webcastbygm.png)](https://www.globalmeet.com)\n\n  * [Outlook ❯](#)\n  * [Google ❯](#)\n\n\n"
        },
        {
          "title": "Citi’s 2024 Global Healthcare Conference",
          "url": "https://kvgo.com/2024-global-healthcare-conference/solid-bio-december",
          "content": "\n"
        },
        {
          "title": "Jefferies London Healthcare Conference",
          "url": "https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=sldb&url=https%3A//wsw.com/webcast/jeff315/sldb/1834980",
          "content": "![Jefferies](/images/resources/jefferies20120920/images/mm_logo.png)\n\n  * [CONFERENCES](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159)\n  * [JEFFERIES HOME](https://www.jefferies.com/)\n\n\n\n# Jefferies London Healthcare Conference\n\n## November 19th - 21st, 2024\n\nTo register for the webcast, please enter your information in the form below.\n\nEvent: |  Jefferies London Healthcare Conference  \n---|---  \nPresentation: |  Solid Biosciences Inc.  \nTime: |  11/20/2024 1:30 PM (GMT)  \n  \nFirst Name* |  First name required  \n---|---  \nLast Name* |  First and last name cannot be the same. Last name required  \nCompany Name* |  Company name required  \nEmail* |  Email required Email is not valid  \n* Required Field  \n  \nYou must have cookies enabled in order to register for this event\n\n[![Summitcast](/images/resources/images/summitcast_logo_sm_black.png)](https://twstevents.com/divisions/summitcast)\n"
        }
      ]
    }
  ]
}